371 related articles for article (PubMed ID: 28619058)
1. The regulatory role of DPP4 in atherosclerotic disease.
Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.
Zhong J; Kankanala S; Rajagopalan S
Curr Opin Lipidol; 2016 Oct; 27(5):484-92. PubMed ID: 27472408
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
4. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
[TBL] [Abstract][Full Text] [Related]
5. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Remm F; Franz WM; Brenner C
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
[TBL] [Abstract][Full Text] [Related]
6. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
7. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.
Gong Q; Rajagopalan S; Zhong J
Int J Cardiol; 2015 Oct; 197():170-9. PubMed ID: 26142202
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
Akoumianakis I; Antoniades C
Vascul Pharmacol; 2017 Sep; 96-98():1-4. PubMed ID: 28697993
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
Matteucci E; Giampietro O
Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl Peptidase 4/Midline-1 Axis Promotes T Lymphocyte Motility in Atherosclerosis.
Rao X; Razavi M; Mihai G; Wei Y; Braunstein Z; Frieman MB; Sun XJ; Gong Q; Chen J; Zhao G; Liu Z; Quon MJ; Dong L; Rajagopalan S; Zhong J
Adv Sci (Weinh); 2023 Mar; 10(9):e2204194. PubMed ID: 36683148
[TBL] [Abstract][Full Text] [Related]
12. The protective role of DPP4 inhibitors in atherosclerosis.
Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
[TBL] [Abstract][Full Text] [Related]
13. Context-dependent effects of dipeptidyl peptidase 4 inhibitors.
Jackson EK
Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):83-90. PubMed ID: 27898522
[TBL] [Abstract][Full Text] [Related]
14. Boning up on DPP4, DPP4 substrates, and DPP4-adipokine interactions: Logical reasoning and known facts about bone related effects of DPP4 inhibitors.
Glorie L; D'Haese PC; Verhulst A
Bone; 2016 Nov; 92():37-49. PubMed ID: 27535784
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Mulvihill EE; Drucker DJ
Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
[TBL] [Abstract][Full Text] [Related]
16. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
17. Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway.
Park DS; Kim K; Jang M; Choi SC
BMB Rep; 2018 Dec; 51(12):636-641. PubMed ID: 30463640
[TBL] [Abstract][Full Text] [Related]
18. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
19. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
Huang J; Liu X; Wei Y; Li X; Gao S; Dong L; Rao X; Zhong J
Front Immunol; 2022; 13():830863. PubMed ID: 35309368
[TBL] [Abstract][Full Text] [Related]
20. DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice.
Herman AB; Tsitsipatis D; Anerillas C; Mazan-Mamczarz K; Carr AE; Gregg JM; Wang M; Zhang J; Michel M; Henry-Smith CA; Harris SC; Munk R; Martindale JL; Piao Y; Fan J; Mattison JA; De S; Abdelmohsen K; Maul RW; Tanaka T; Moore AZ; DeMouth ME; Sidoli S; Ferrucci L; Liu Y; de Cabo R; Lakatta EG; Gorospe M
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37097759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
